Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genedx Holdings Corp (WGS)

Genedx Holdings Corp (WGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,768,103
  • Shares Outstanding, K 29,289
  • Annual Sales, $ 427,540 K
  • Annual Income, $ -21,020 K
  • EBIT $ -13 M
  • EBITDA $ 12 M
  • 60-Month Beta 2.03
  • Price/Sales 6.04
  • Price/Cash Flow 38.44
  • Price/Book 8.36

Options Overview Details

View History
  • Implied Volatility 75.97% (+2.05%)
  • Historical Volatility 79.12%
  • IV Percentile 51%
  • IV Rank 21.70%
  • IV High 157.37% on 04/07/25
  • IV Low 53.41% on 08/28/25
  • Expected Move (DTE 3) 3.87 (4.18%)
  • Put/Call Vol Ratio 4.80
  • Today's Volume 174
  • Volume Avg (30-Day) 1,113
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 11,974
  • Open Int (30-Day) 13,694
  • Expected Range 88.71 to 96.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -121.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.55 +31.29%
on 03/03/26
97.30 -7.50%
on 02/11/26
-4.78 (-5.04%)
since 02/10/26
3-Month
68.55 +31.29%
on 03/03/26
158.22 -43.12%
on 12/11/25
-68.57 (-43.24%)
since 12/10/25
52-Week
55.17 +63.13%
on 05/08/25
170.87 -47.33%
on 12/02/25
+0.34 (+0.38%)
since 03/10/25

Most Recent Stories

More News
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

ZVRA : 11.09 (+21.60%)
WGS : 91.15 (-3.56%)
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

WGS : 91.15 (-3.56%)
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

WGS : 91.15 (-3.56%)
GeneDx to Participate in Upcoming Investor Conferences

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:...

WGS : 91.15 (-3.56%)
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) ...

WGS : 91.15 (-3.56%)
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

Recognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes

WGS : 91.15 (-3.56%)
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens...

WGS : 91.15 (-3.56%)
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

WGS : 91.15 (-3.56%)
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth quarter 2025...

WGS : 91.15 (-3.56%)
GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

GeneDx’s Infinity™ will leverage insights from Komodo’s Healthcare Map ® to unlock faster health economics and outcomes research (HEOR), biopharma innovation,...

WGS : 91.15 (-3.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn.

See More

Key Turning Points

3rd Resistance Point 108.64
2nd Resistance Point 102.01
1st Resistance Point 98.26
Last Price 91.15
1st Support Level 87.88
2nd Support Level 81.25
3rd Support Level 77.50

See More

52-Week High 170.87
Fibonacci 61.8% 126.67
Fibonacci 50% 113.02
Fibonacci 38.2% 99.37
Last Price 91.15
52-Week Low 55.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar